We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.11%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$64M
Cap. Flow
-$23.9M
Cap. Flow %
-0.91%
Top 10 Hldgs %
39.72%
Holding
198
New
11
Increased
45
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$17.5M
2
SYK icon
Stryker
SYK
+$12.2M
3
AZN icon
AstraZeneca
AZN
+$12.1M
4
DHR icon
Danaher
DHR
+$11.9M
5
PFE icon
Pfizer
PFE
+$11.1M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$13.6M
2
SHPG
Shire pic
SHPG
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$12.3M
4
ABT icon
Abbott
ABT
+$10.4M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.69M

Sector Composition

Rank Sector Weight
1 Healthcare 94.11%
2 Real Estate 3%
3 Miscellaneous 2.21%
4 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HR icon
151
Healthcare Realty
HR
$6.34B
$1.24M 0.05%
46,000
– –
DOC icon
152
Healthpeak Properties
DOC
$14B
$1.18M 0.04%
45,500
– –
MNK
153
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$1.16M 0.04%
61,900
– –
NUVA
154
DELISTED
NuVasive, Inc.
NUVA
$1.02M 0.04%
+19,580
New +$1.03M
NSTG
155
DELISTED
NanoString Technologies, Inc.
NSTG
$1.02M 0.04%
74,250
– –
LUMO
156
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$976K 0.04%
22,781
– –
LMAT icon
157
LeMaitre Vascular
LMAT
$1.84B
$909K 0.03%
+27,150
New +$966K
CLSD
158
DELISTED
Clearside Biomedical
CLSD
$884K 0.03%
+5,511
New +$929K
CDTX
159
DELISTED
Cidara Therapeutics
CDTX
$826K 0.03%
7,939
– –
HOLX
160
DELISTED
Hologic
HOLX
$777K 0.03%
19,546
– –
NVAX icon
161
Novavax
NVAX
$1.54B
$765K 0.03%
28,550
– –
MTEM
162
DELISTED
Molecular Templates, Inc.
MTEM
$754K 0.03%
9,607
+6,081
+172% +$689K
CYH icon
163
Community Health Systems
CYH
$420M
$677K 0.03%
203,935
– –
XRN
164
Chiron Real Estate Inc
XRN
$473M
$650K 0.02%
14,680
– –
LIVN icon
165
LivaNova
LIVN
$4.33B
$628K 0.02%
+6,287
New +$571K
RMR icon
166
The RMR Group
RMR
$323M
$584K 0.02%
7,441
– –
ORKA
167
Oruka Therapeutics
ORKA
$6.19B
$451K 0.02%
3,756
– –
BLCM
168
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$443K 0.02%
6,000
– –
IOVA icon
169
Iovance Biotherapeutics
IOVA
$4.48B
$427K 0.02%
+33,395
New +$488K
ASRT
170
DELISTED
Assertio
ASRT
$420K 0.02%
+1,050
New +$427K
ADYX
171
DELISTED
Adynxx Inc
ADYX
$338K 0.01%
27,500
– –
CAH icon
172
Cardinal Health
CAH
$54.1B
$308K 0.01%
6,300
– –
AGIO icon
173
Agios Pharmaceuticals
AGIO
$1.97B
$237K 0.01%
2,810
– –
NCNA
174
NuCana
NCNA
$5.45M
$187K 0.01%
2
-3
-60% -$369K
TBPH icon
175
Theravance Biopharma
TBPH
$885M
$183K 0.01%
8,083
– –
4 5 6
7
8

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Tekla Capital Management held 198 positions worth $2.64B, up 2.5% from $2.57B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2018 filing shows 11 new, 45 increased, 37 reduced and 18 closed positions. Its largest new stake was Whitehawk Therapeutics: 51,000 shares worth $3.17M. The largest sale was Sarepta Therapeutics, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate and Miscellaneous.

  • Tekla Capital Management's largest Q2 2018 buy was Whitehawk Therapeutics: 51,000 shares worth $3.17M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2018, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2018 reduction was Sarepta Therapeutics, cutting an estimated $13.6M.
  • Tekla Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $8.69M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.64B portfolio in Q2 2018.
  • Tekla Capital Management opened 11 new positions and closed 18 in Q2 2018.
  • Tekla Capital Management's portfolio value rose 2.5% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.